GO ALL IN FROM THE START

INREBIC® is a JAK2-selective inhibitor that
can be given at full dose from the start

GO ALL IN FROM THE START

INREBIC® is a JAK2-selective inhibitor that
can be given at full dose from the start

Eligible patients can start at
the full dose of INREBIC®1

400 mg qd INREBIC®for patients with platelets ≥50 × 109/L*

Adult patients can receive INREBIC® if they
have:
  • Intermediate-2 or high-risk primary or
    secondary (post-PV or post-ET) myelofibrosis
  • Baseline platelet count ≥50 × 109/L
Get patients started

ET, essential thrombocythemia; JAK, Janus-associated kinase; PV, polycythemia vera; qd, once daily.

*Reduce dose to 200 mg qd for patients using concomitant strong CYP3A4 inhibitors or those with severe renal impairment. Avoid use in patients receiving strong and moderate CYP3A4 inducers, those receiving dual CYP3A4 and CYP2C19 inhibitors, and those with severe hepatic impairment.

Two men and a woman rest near a rock Two men and a woman rest near a rock

ET, essential thrombocythemia; JAK, Janus-associated kinase; PV, polycythemia vera; qd, once daily.

*Reduce dose to 200 mg qd for patients using concomitant strong CYP3A4 inhibitors or those with severe renal impairment. Avoid use in patients receiving strong and moderate CYP3A4 inducers, those receiving dual CYP3A4 and CYP2C19 inhibitors, and those with severe hepatic impairment.

INREBIC® is a highly selective
inhibitor of JAK21

  • JAK2 activation iconAbnormal activation of JAK2 is associated with MPNs including myelofibrosis and PV
  • JAK2/FLT3 shield iconINREBIC® has activity against wild-type and mutated JAK2, as well as FLT3
  • JAK2 magnifying glass iconINREBIC® has higher affinity for JAK2 over family members JAK1, JAK3, and TYK2

FLT, FMS-like tyrosine kinase; MPNs, myeloproliferative neoplasms; TYK, tyrosine kinase. Based on preclinical data; these statements do not imply clinical outcomes.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.